Berenson Stephen 4

What Happened Stephen Berenson, a director of Seres Therapeutics (MCRB), received a grant/award of rights to 6,500 shares (reported as a derivative award) on July 8, 2026. The Form 4 records the acquisition price as $0.00 and lists the transaction code A (award/grant). The award is an option-like award that will vest and become exercisable by the earlier of July 8, 2027 or the day before the first annual meeting of stockholders after July 8, 2026.

Key Details

• Transaction date: July 8, 2026; Form 4 filed July 10, 2026 (filed within the usual two-business-day window).
• Transaction type/code: A = Award/Grant (derivative security). Reported price on Form 4: $0.00 per share (total recorded value $0 on the filing).
• Shares awarded: 6,500 (derivative/option grant).
• Vesting: Vests and becomes exercisable on the earlier of (i) July 8, 2027 or (ii) the day before the first annual meeting of stockholders occurring after July 8, 2026 (per footnote).
• Shares owned after transaction: Not specified in the provided excerpt of the filing — see the full Form 4 for total beneficial ownership.
• Filing timeliness: Not late (filed July 10 for a July 8 transaction).

Context This was an equity award (derivative grant) typically used for director compensation; it does not represent an open-market purchase or sale and does not indicate any immediate sale of shares. The award will only become exercisable if/when it vests per the schedule above. For full economic terms (exercise price, expiration, and other conditions), consult the complete Form 4 and related grant agreement or the company’s proxy/SEC filings.